Chronic Administration of the Glucagon-Like Peptide-1 Analog, Liraglutide, Delays the Onset of Diabetes and Lowers Triglycerides in UCD-T2DM Rats
Bethany P. Cummings(Metabolic Solutions), Peter J. Havel(University of British Columbia), Kirsten Raun(Novo Nordisk (Denmark)), James L. Graham(Western Human Nutrition Research Center), Lotte Bjerre Knudsen(Novo Nordisk (Denmark)), Denis G. Baskin(University of Washington), Cecilia Nilsson(Swedish Medical Association), Steven C. Griffen(Io Therapeutics (United States)), Anette Sams(Glostrup Hospital), Kimber L. Stanhope(University of California, Davis)
Cited by 73
Related Papers
Consuming fructose-sweetened, not glucose-sweetened, beverages increases visceral adiposity and lipids and decreases insulin sensitivity in overweight/obese humans
|Journal of Clinical Investigation|2009|1.7k
Fructose, weight gain, and the insulin resistance syndrome,,
|American Journal of Clinical Nutrition|2002|1k
The arcuate nucleus mediates GLP-1 receptor agonist liraglutide-dependent weight loss
|Journal of Clinical Investigation|2014|913
The Discovery and Development of Liraglutide and Semaglutide
|Frontiers in Endocrinology|2019|890
Dietary Fructose Reduces Circulating Insulin and Leptin, Attenuates Postprandial Suppression of Ghrelin, and Increases Triglycerides in Women
|The Journal of Clinical Endocrinology & Metabolism|2004|747